{"id":"mk-1084","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL5939127","moleculeType":null,"molecularWeight":"392.46"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NK1 receptor antagonism reduces the transmission of pain and emetic signals by blocking substance P, a neuropeptide involved in pain perception and nausea/vomiting pathways. This mechanism has been explored for chronic pain conditions and chemotherapy-induced nausea and vomiting (CINV).","oneSentence":"MK-1084 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:38.140Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain conditions (investigational)"},{"name":"Chemotherapy-induced nausea and vomiting (CINV) (investigational)"}]},"trialDetails":[{"nctId":"NCT06997497","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-16","conditions":"Colon Adenocarcinoma, Rectal Adenocarcinoma","enrollment":477},{"nctId":"NCT07209111","phase":"PHASE2","title":"A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-04","conditions":"Neoplasm Malignant","enrollment":150},{"nctId":"NCT07190248","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-08","conditions":"Non-small Cell Lung Cancer","enrollment":675},{"nctId":"NCT07252739","phase":"PHASE2","title":"KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-19","conditions":"Malignant Neoplasm","enrollment":130},{"nctId":"NCT06345729","phase":"PHASE3","title":"A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-24","conditions":"Non-small Cell Lung Cancer","enrollment":600},{"nctId":"NCT07286149","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-23","conditions":"Lung Neoplasm Malignant","enrollment":190},{"nctId":"NCT05853367","phase":"PHASE1","title":"Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-07-06","conditions":"Metastatic Solid Tumors, Advanced Solid Tumors","enrollment":178},{"nctId":"NCT07219550","phase":"PHASE1","title":"A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-05","conditions":"Healthy, Hepatic Impairment","enrollment":58},{"nctId":"NCT07431827","phase":"PHASE3","title":"MK-3475A±MK-1084 in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-04-01","conditions":"Non-small Cell Lung Cancer","enrollment":400},{"nctId":"NCT06814119","phase":"PHASE1","title":"A Clinical Study of Calderasib (MK-1084) in Participants With Renal Impairment (MK-1084-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-07","conditions":"Healthy, Renal Impairment","enrollment":34},{"nctId":"NCT05067283","phase":"PHASE1","title":"A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-12-17","conditions":"Advanced Solid Tumors","enrollment":830},{"nctId":"NCT06575933","phase":"PHASE1","title":"A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-09-03","conditions":"Non-small Cell Lung Cancer","enrollment":28},{"nctId":"NCT06619314","phase":"PHASE1","title":"A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-09-20","conditions":"Healthy","enrollment":56},{"nctId":"NCT06719557","phase":"PHASE1","title":"A Study of the Effect of Itraconazole and Phenytoin on Calderasib (MK-1084) in Healthy Adults (MK-1084-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-20","conditions":"Healthy","enrollment":28},{"nctId":"NCT07222098","phase":"PHASE1","title":"A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-19","conditions":"Healthy","enrollment":16},{"nctId":"NCT06942741","phase":"PHASE1","title":"A Study to Evaluate the Effect of Formulation and Food on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-13","conditions":"Healthy","enrollment":52},{"nctId":"NCT06687759","phase":"PHASE1","title":"A Study of MK-1084 Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-26","conditions":"Healthy","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MK-1084","genericName":"MK-1084","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MK-1084 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system. Used for Chronic pain conditions (investigational), Chemotherapy-induced nausea and vomiting (CINV) (investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}